Bashar A. Aqel, MD, Mayo Clinic, Phoenix, Arizona, presented results from phase 2 of the COSMOS (Combination Of SiMeprevir and sOfosbuvir in hepatitis C virus genotype 1 infected patients) trial. On ...
Hepatitis C’s second wave has crested and crashed, and this gold rush looks like it will be succeeded by a new generation of more effective, if less lucrative agents. Predictably, Gilead Sciences ...
This approval marks the first time patients with chronic hepatitis C virus (HCV) genotype 3 have a 12-week, once-daily, all-oral treatment option. Daklinza is indicated for use with sofosbuvir for the ...
Gilead said on Friday that an advisory committee unanimously recommended approval of an all-oral regimen containing its hepatitis C drug sofosbuvir and ribavirin in patients with genotypes 2 and 3.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results